(S)-2-叔丁氧基羰基氨基-3-(3-羟基苯基)-丙酸 | 90819-30-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-叔丁氧基羰基氨基-3-(3-羟基苯基)-丙酸
• 中文别名: N-BOC-3-羟基-L-苯丙氨酸
• 英文名称: (S)-2-((tert-butoxycarbonyl)amino)-3-(3-hydroxyphenyl)propanoic acid
• 英文别名: Boc-L-m-tyrosine；(2S)-2-(tert-butoxycarbonylamino)-3-(3-hydroxyphenyl)propanoic acid；Boc-(S)-2-amino-3-(3-hydroxyphenyl)propionic acid；(S)-2-Tert-butoxycarbonylamino-3-(3-hydroxy-phenyl)-propionic acid；(2S)-3-(3-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 90819-30-0
• 化学式: C₁₄H₁₉NO₅
• 分子量: 281.309
• InChiKey: FABANBOJFXYSHH-NSHDSACASA-N

物化性质

• 沸点：
  486.4±40.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-2-tert-Butoxycarbonylamino-3-(3-hydroxy-phenyl)-propionic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-2-tert-Butoxycarbonylamino-3-(3-hydroxy-phenyl)-propionic acid
CAS number: 90819-30-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H19NO5
Molecular weight: 281.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-2-叔丁氧基羰基氨基-3-(3-羟基苯基)-丙酸 在 咪唑 、 三氟甲磺酸三甲基硅酯 、 sodium hydride 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 79.42h， 生成 (S)-1-{(S)-2-[(S)-2-tert-butoxycarbonylamino-3-(4-methoxy-phenyl)-propionylamino]-3-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-propionyl}-hexahydro-pyridazine-3-carboxylic acid but-3-enyl ester
  参考文献：
  名称：

  [EN] MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
  [FR] INHIBITEURS MACROCYCLIQUES DE VIRUS FLAVIVIRIDAE

  摘要：

  提供的是化合物的化学式(I)及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗黄病毒科病毒感染，特别是丙型肝炎感染是有用的。

  公开号：

  WO2012078915A1
• 作为产物：
  描述：

  DL-间酪氨酸 在 三乙胺 、 α-chymotrypsin 作用下， 反应 24.0h， 生成 (S)-2-叔丁氧基羰基氨基-3-(3-羟基苯基)-丙酸
  参考文献：
  名称：

  通过REMA方法合成[L- m -Tyr 1 ]-和[D- m -Tyr 1 ]-亮氨酸-脑啡肽

  摘要：

  描述了亮氨酸-脑啡肽的两个类似物，即通过全重复-过量-混合-酸酐（REMA）方法进行的合成。[L-米-Tyr 1 ] -和[D-米-Tyr 1 ] -亮氨酸-脑啡肽，利用酶促解决（的米-羟基苯基）丙氨酸（米-酪氨酸）。

  DOI：

  10.1002/recl.19841030402

文献信息

• Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity
  作者：Yuma Terasawa、Chisato Sataka、Toyotaka Sato、Kazuki Yamamoto、Yukari Fukushima、Chie Nakajima、Yasuhiko Suzuki、Akira Katsuyama、Takanori Matsumaru、Fumika Yakushiji、Shin-ichi Yokota、Satoshi Ichikawa

  DOI：10.1021/acs.jmedchem.0c00973

  日期：2020.9.10

  The synthesis and biological evaluation of analogues of uridylpeptide antibiotics were described, and the molecular interaction between the 3′-hydroxy analogue of mureidomycin A (3′-hydroxymureidomycin A) and its target enzyme, phospho-MurNAc-pentapeptide transferase (MraY), was analyzed in detail. The structure–activity relationship (SAR) involving MraY inhibition suggests that the side chain at the

  描述了尿苷肽抗生素类似物的合成和生物学评估，并证明了莫来霉素A（3'-羟基尿素霉素A）的3'-羟基类似物与其靶酶磷酸-MurNAc-五肽转移酶（MraY）之间的分子相互作用。详细分析。涉及MraY抑制的结构活性关系（SAR）表明，尿素-二肽部分的侧链不影响MraY抑制。但是，抗铜绿假单胞菌活性形成了鲜明的对比，而尿素-二肽基序是关键的贡献者。还建议核苷肽渗透酶NppA1A2BCD负责3'-羟基mureidomycin A进入细胞质的转运。进一步进行了3'-羟基mureidomycin A尿素-二肽部分的系统SAR分析，并确定了抗菌活性。该研究为基于尿苷肽抗生素的类似物的合理设计提供了指导。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015061518A1

  公开（公告）日：2015-04-30

  Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula :(I)

  具有抗艾滋病毒活性的I类化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的药物组合物和使用这些化合物的方法，如下所示：Formula :(I)
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS DE STABILISATION DE LA TRANSTHYRÉTINE ET D'INHIBITION DU MAUVAIS REPLIEMENT DE LA TRANSTHYRÉTINE
  申请人：PROTEGO BIOPHARMA INC

  公开号：WO2021154842A1

  公开（公告）日：2021-08-05

  Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.

  本文件提供了对TTR相关疾病具有活性的化合物，以及可被药物接受的盐和溶剂化物。还提供了使用这些化合物来抑制和预防外周神经、肾脏、心肌组织、眼睛和中枢神经系统的TTR聚集和/或淀粉样蛋白形成的方法，以及治疗患有外周TTR淀粉样变性的主体的方法。
• Substituted hydantoins
  申请人：Goodnow, Alan Robert

  公开号：US20060063814A1

  公开（公告）日：2006-03-23

  The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

  本发明涉及以下公式的化合物，这些化合物在治疗以MEK高活性为特征的疾病方面具有用途。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病方面具有用途。
• Aminodiol HIV Protease Inhibitors. Synthesis And Structure−Activity Relationships Of P₁/P₁‘ Compounds:  Correlation between Lipophilicity and Cytotoxicity
  作者：Ping Chen、Peter T. W. Cheng、Masud Alam、Barbara D. Beyer、Gregory S. Bisacchi、Tamara Dejneka、Adelaide J. Evans、Jill A. Greytok、Mark A. Hermsmeier、W. Griffith Humphreys、Glenn A. Jacobs、Octavian Kocy、Pin-Fang Lin、Karen A. Lis、Michael A. Marella、Denis E. Ryono、Amy K. Sheaffer、Steven H. Spergel、Chong-qing Sun、Joseph A. Tino、Gregory Vite、Richard J. Colonno、Robert Zahler、Joel C. Barrish

  DOI：10.1021/jm950717a

  日期：1996.1.1

  A series of novel aminodiol inhibitors of HIV protease based on the lead compound 1 with structural modifications at P1' were synthesized in order to reduce the cytotoxicity of 1. We have observed a high degree of correlation between the lipophilicity and cytotoxicity of this series of inhibitors. It was found that appropriate substitution at the para position of the P1' phenyl group of 1 resulted

  为了减少1的细胞毒性，合成了一系列基于P1'结构修饰的先导化合物1的HIV蛋白酶的新型氨基二醇抑制剂。我们已经观察到该系列抑制剂的亲脂性和细胞毒性之间存在高度相关性。 。发现在P1'苯基基团对位1处的适当取代导致鉴定出等价的（对酶和细胞培养均如此）化合物（10l，10m，10n和15c），这些化合物具有明显降低的细胞毒性。